1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
2025 Translational Aging Research pilot grants is sponsored by UTHealth Houston Institute on Aging. The Institute on Aging seeks proposals exploring hypotheses regarding how to enhance resilience in the face of social adversity, and how experiences of social adversity across the lifespan affect biological aging processes to increase susceptibility to disability, morbidity, and mortality among older adults.
Research related to aging bone and early detection methods like opportunistic osteoporosis screening could be relevant.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: These grants are intended to support pilot studies in aging research and are aimed at faculty who have not previously received support through this program. The primary objective of these awards is to provide preliminary funding for aging-related research that will enable researchers to develop their projects and enhance their prospects for securing larger extramural grants. Confirm the full requirements in the official notice before applying.
The current listing shows $7,500 - $15,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
2025 Translational Aging Research pilot grants is funded by UTHealth Houston Institute on Aging. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Seven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read articleARPA-H awarded $144M across 7 research teams to run the first clinical trials treating aging as a condition — not a disease. How PROSPR reshapes longevity funding and what grant seekers in biotech, academia, and health tech should know.
Read article